NCT02573272Unknown不适用
Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud1 个研究点 分布在 1 个国家目标入组 204 人开始时间: 2015年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 204
- 试验地点
- 1
- 主要终点
- Carotid IMT millimeters
研究概览
简要总结
Knowing the impact that the use of ESL as adjunctive treatment of partial epilepsy has on cardiovascular risk factors measured by biochemical and ultrasound parameters compared with enzyme-inducing AEDs.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients over 18 years
- •patients definitively diagnosed Focal Epilepsy based on clinical criteria and additional tests.
- •patients with stable and identifiable antiepileptic treatment during the last two years.
- •patients according to the investigator are able to provide clinical data necessary for the development of the study
- •Patients who signed informed consent
排除标准
- •Patients who, according to their evolution and demands of clinical practice, their previous treatment has to be changed for this reason breach inclusion criteria and / or attachment to one of the study groups.
研究组 & 干预措施
Epileptic patients with AEDs and eslicarbacepine
干预措施: eslicarbacepine (Drug)
结局指标
主要结局
Carotid IMT millimeters
时间窗: one year
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
The Effect of Levetiracetam on Lipid Profile in ChildrenEpilepsyChild, OnlyThyroidLipid DisorderNCT05276271Ege University91
终止
不适用
Antiepileptic Drugs and Vascular Risk MarkersSubarachnoid HemorrhageNCT00774306Thomas Jefferson University52
已完成
4 期
Effects of Ezetimibe on Postprandial Hyperlipidemia and Endothelial FunctionMetabolic SyndromeNCT00189085UMC Utrecht20
终止
3 期
A Study of Evacetrapib in High-Risk Vascular DiseaseCardiovascular DiseasesNCT01687998Eli Lilly and Company12,092
已完成
1 期
Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy VolunteersNeuropathic PainNCT00971295Bial - Portela C S.A.20